疑似多发性硬化的鉴别诊断:北美、北欧和澳大拉西亚少数族裔和种族背景人群的考量
该综述指出疑似多发性硬化的鉴别诊断基于北美、北欧和澳大拉西亚的白人人群数据,而高患病率地区少数族裔和种族背景人群更常受健康社会决定因素负面影响,在考虑多发性硬化诊断时需综合移民、诊断不平等和社会决定因素的复杂交互。
要点
- 少数族裔和种族背景人群在多发性硬化高患病率地区更常受健康社会决定因素负面影响。
- 对北美、北欧和澳大拉西亚的少数族裔和种族背景人群,鉴别诊断需考虑视神经脊髓炎、系统性红斑狼疮、神经结节病、感染和脑血管病(如高血压)。
- 诊断需综合考量移民、诊断不平等和健康社会决定因素的复杂交互。
核心结论
- 在北美、北欧和澳大拉西亚,少数族裔和种族背景人群疑似多发性硬化的诊断需综合考量移民、诊断不平等和健康社会决定因素的复杂交互。
研究设计与样本
- 综述,基于北美、北欧和澳大拉西亚的数据,聚焦白人人群。
主要发现
- 少数族裔和种族背景人群在多发性硬化高患病率地区更常受健康社会决定因素负面影响。
- 对北美、北欧和澳大拉西亚的少数族裔和种族背景人群,鉴别诊断需考虑视神经脊髓炎、系统性红斑狼疮、神经结节病、感染和脑血管病(如高血压)。
临床怎么用
- 在考虑多发性硬化诊断时,对北美、北欧和澳大拉西亚的少数族裔和种族背景人群需综合考量移民、诊断不平等和健康社会决定因素的复杂交互。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The differential diagnosis of suspected multiple sclerosis has been developed using data from North America, northern Europe, and Australasia, with a focus on White populations. People from minority ethnic and racial backgrounds in regions where prevalence of multiple sclerosis is high are more often negatively affected by social determinants of health, compared with White people in these regions. A better understanding of changing demographics, the clinical characteristics of people from minority ethnic or racial backgrounds, and the social challenges they face might facilitate equitable clinical approaches when considering a diagnosis of multiple sclerosis. Neuromyelitis optica, systemic lupus erythematous, neurosarcoidosis, infections, and cerebrovascular conditions (eg, hypertension) should be considered in the differential diagnosis of multiple sclerosis for people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia. The diagnosis of multiple sclerosis in people from a minority ethnic or racial background in these regions requires a comprehensive approach that considers the complex interplay of immigration, diagnostic inequity, and social determinants of health.
引用
- Amezcua L, Rotstein D, Shirani A, et al. Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia. Lancet Neurol. 2024. PMID: 39304244. doi:10.1016/S1474-4422(24)00288-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。